» Articles » PMID: 31078164

Cancers Attributable to Infections in Canada

Overview
Journal Prev Med
Specialty Public Health
Date 2019 May 13
PMID 31078164
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Infections are estimated to cause approximately 15% of the world's cancers with large geographic variations. Yet, Canadian estimates for specific cancer-causing infections are not available. To estimate the number of infection-associated cancers diagnosed among Canadian adults in 2015, we calculated population attributable risks (PARs) and the number of attributable cases for seven carcinogenic infections and their 20 associated cancers. A systematic literature search was performed for each infection to obtain data on infection prevalence in the population and the relative risk or odds ratio associated with the cancer it causes. When mechanistic evidence suggested that detection of a given infection within cancer tissue was sufficient to attribute the cancer to the infection, prevalence among cancer cases was used to approximate the PAR. Data from 61 studies formed the basis of our analyses. The estimated number of infection-attributable cancer cases for 2015 was: 3828 for human papillomavirus (HPV), 2052 for Helicobacter pylori, 578 for Epstein-Barr virus, 509 for hepatitis B and C viruses (HBV, HCV), 100 for human herpesvirus type 8, and 30 cases for human T-cell lymphotropic virus type 1. These seven infections were responsible for 3.7% of cancers diagnosed among Canadian adults in 2015; 3.5% among men and 4.0% among women. The infections with the highest number of attributable cases are largely preventable or treatable through vaccination (HBV and HPV), antibiotic therapy (H. pylori), or a combination of interventions (HCV), thereby representing an important target for reducing the infection-caused cancer burden among Canadians.

Citing Articles

Shooting for the Moon: Can We Cut Cancer Mortality in Canada By 50% By 2050?.

Banik K, Ruan Y, Stephen M, Hutchinson J, Carbonell C, Warkentin M Cancer Control. 2025; 32:10732748251319485.

PMID: 39943836 PMC: 11822815. DOI: 10.1177/10732748251319485.


Social capital interventions for human papillomavirus (HPV) immunization and cervical cancer screening: A rapid review.

Gillies C, Allen-Scott L, Nykiforuk C, Belon A, Kim M, Lee B Can Commun Dis Rep. 2024; 50(7-8):260-273.

PMID: 39170590 PMC: 11321452. DOI: 10.14745/ccdr.v50i78a04.


MUC1 promotes cervical squamous cell carcinoma through ERK phosphorylation-mediated regulation of ITGA2/ITGA3.

Zhao A, Pan Y, Gao Y, Zhi Z, Lu H, Dong B BMC Cancer. 2024; 24(1):559.

PMID: 38702644 PMC: 11069143. DOI: 10.1186/s12885-024-12314-6.


Individual and Geospatial Determinants of Health Associated With School-Based Human Papillomavirus Immunization in Alberta: Population-Based Cohort Study.

Malkin J, Jessiman-Perreault G, Alberga Machado A, Teare G, Snider J, Tirmizi S JMIR Public Health Surveill. 2024; 10():e45508.

PMID: 38536211 PMC: 11007603. DOI: 10.2196/45508.


Screening for High-Risk Human Papillomavirus Reveals HPV52 and HPV58 among Pediatric and Adult Patient Saliva Samples.

Hinton H, Herrera L, Valenzuela S, Howard K, Kingsley K Dent J (Basel). 2024; 12(3).

PMID: 38534280 PMC: 10969671. DOI: 10.3390/dj12030056.